Compound Danshen Dripping Pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR...

Area of Science:

• Cardiovascular Research
• Pharmacology
• Molecular Biology

Background:

• Heart failure is a major global health concern.
• Compound Danshen Dripping Pill (CDDP) is used for cardiovascular diseases in China.
• The effect of CDDP on hypercholesterolemia/atherosclerosis-induced heart failure is not well understood.

Purpose of the Study:

• To investigate the efficacy of CDDP, alone or with simvastatin, on heart failure induced by hypercholesterolemia/atherosclerosis.
• To elucidate the underlying molecular mechanisms of CDDP's action in this heart failure model.

Main Methods:

• A novel mouse model of heart failure was created using apolipoprotein E (ApoE) and LDL receptor (LDLR) dual deficient mice.
• Mice were treated with CDDP or a combination of CDDP and low-dose simvastatin.
• Key molecular pathways, including Wnt and KDM4A, were analyzed.

Main Results:

• CDDP and CDDP/simvastatin combination significantly inhibited heart injury, myocardial dysfunction, and fibrosis.
• Both treatments suppressed the activated Wnt pathway by up-regulating Wnt inhibitors.
• CDDP reduced inflammation and oxidative stress by inhibiting KDM4A expression and activity.
• CDDP also mitigated simvastatin-induced skeletal muscle myolysis.

Conclusions:

• CDDP, alone or with simvastatin, demonstrates therapeutic potential against hypercholesterolemia/atherosclerosis-induced heart failure.
• The mechanisms involve modulation of Wnt and KDM4A pathways, alongside anti-inflammatory and anti-oxidative effects.
• CDDP offers a promising treatment strategy with potential benefits for skeletal muscle health.